Profiling of circulating microRNAs for prostate cancer biomarker discovery

Drug Delivery and Translational Research

Volumn 4, Issue 1, 2014, Pages 19-30

  Haldrup, Christa ^a   Kosaka, Nobuyoshi ^b   Ochiya, Takahiro ^b   Borre, Michael ^a   Høyer, Soren ^a   Orntoft, Torben F ^a   Sorensen, Karina D ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Biomarker; Circulation; miRNA; Molecular diagnostics; Prostate cancer; Serum

Indexed keywords

MICRORNA; MICRORNA 107; MICRORNA 1203; MICRORNA 141; MICRORNA 17; MICRORNA 200A; MICRORNA 200B; MICRORNA 210; MICRORNA 375; MICRORNA 501; MICRORNA 501 3P; MICRORNA 551B; MICRORNA 562; MICRORNA 609; MICRORNA 616; MICRORNA 708; MOLECULAR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DISTANT METASTASIS; GLEASON SCORE; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN BLOOD LEVEL; SERUM;

EID: 84893590923     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-013-0169-4     Document Type: Article

References (38)

1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46(4): 765-81. doi: 10. 1016/j. ejca. 2009. 12. 014.
2. Hoogendam A, Buntinx F, de Vet HC. The diagnostic value of digital rectal examination in primary care screening for prostate cancer: a meta-analysis. Family Practice. 1999;16(6): 621-6.
3. Glaser AP, Novakovic K, Helfand BT. The impact of prostate biopsy on urinary symptoms, erectile function, and anxiety. Current Urol Reports. 2012;13(6): 447-54. doi: 10. 1007/s11934-012-0277-6.
4. Wolters T, van der Kwast TH, Vissers CJ, Bangma CH, Roobol M, Schroder FH, et al. False-negative prostate needle biopsies: frequency, histopathologic features, and follow-up. The Am J Surg Pathol. 2010;34(1): 35-43. doi: 10. 1097/PAS. 0b013e3181c3ece9.
5. Albertsen PC. Treatment of localized prostate cancer: when is active surveillance appropriate? Nature Rev Clin Oncol. 2010;7(7): 394-400. doi: 10. 1038/nrclinonc. 2010. 63.
6. Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R, Kerin MJ. Systemic miRNAs as potential biomarkers for malignancy. Int J Cancer. 2012;131(10): 2215-22. doi: 10. 1002/ijc. 27642.
7. Zhou L, Zhao YP, Liu WJ, Dong J, Chen WY, Zhang TP, et al. Circulating microRNAs in cancer: diagnostic and prognostic significance. Expert Rev of Anticancer Ther. 2012;12(2): 283-8. doi: 10. 1586/era. 11. 197.
8. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10): 997-1006. doi: 10. 1038/cr. 2008. 282.
9. Chen X, Liang H, Zhang J, Zen K, Zhang CY. Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 2012;22(3): 125-32. doi: 10. 1016/j. tcb. 2011. 12. 001.
10. Cocucci E, Racchetti G, Meldolesi J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 2009;19(2): 43-51. doi: 10. 1016/j. tcb. 2008. 11. 003.
11. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nature Rev Immunol. 2002;2(8): 569-79. doi: 10. 1038/nri855.
12. Ratajczak J, Wysoczynski M, Hayek F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukemia. 2006;20(9): 1487-95. doi: 10. 1038/sj. leu. 2404296.
13. Simons M, Raposo G. Exosomes-vesicular carriers for intercellular communication. Current Opinion in Cell Biol. 2009;21(4): 575-81. doi: 10. 1016/j. ceb. 2009. 03. 007.
14. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. 2011;13(4): 423-33. doi: 10. 1038/ncb2210.
15. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011;108(12): 5003-8. doi: 10. 1073/pnas. 1019055108.
16. Turchinovich A, Weiz L, Langheinz A, Burwinkel B. Characterization of extracellular circulating microRNA. Nucleic Acids Res. 2011;39(16): 7223-33. doi: 10. 1093/nar/gkr254.
17. Ma R, Jiang T, Kang X. Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res: CR. 2012;31: 38. doi: 10. 1186/1756-9966-31-38.
18. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008;105(30): 10513-8. doi: 10. 1073/pnas. 0804549105.
19. Kelly BD, Miller N, Healy NA, Walsh K, Kerin MJ. A review of expression profiling of circulating microRNAs in men with prostate cancer. BJU Int. 2013;111(1): 17-21. doi: 10. 1111/j. 1464-410X. 2012. 11244. x.
20. Selth LA, Tilley WD, Butler LM. Circulating microRNAs: macro-utility as markers of prostate cancer? Endocrine-related cancer. 2012;19(4): R99-R113. doi: 10. 1530/ERC-12-0010.
21. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004;64(15): 5245-50. doi: 10. 1158/0008-5472. CAN-04-0496.
22. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1): 11-22. doi: 10. 1016/j. ccr. 2010. 05. 026.
23. Bryant RJ, Pawlowski T, Catto JW, Marsden G, Vessella RL, Rhees B, et al. Changes in circulating microRNA levels associated with prostate cancer. British J Cancer. 2012;106(4): 768-74. doi: 10. 1038/bjc. 2011. 595.
24. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011;128(3): 608-16. doi: 10. 1002/ijc. 25376.
25. Nguyen HC, Xie W, Yang M, Hsieh CL, Drouin S, Lee GS, et al. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Prostate. 2012. doi: 10. 1002/pros. 22572.
26. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One. 2009;4(7): e6229. doi: 10. 1371/journal. pone. 0006229.
27. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stoppler H, et al. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res. 2011;71(2): 550-60. doi: 10. 1158/0008-5472. CAN-10-1229.
28. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, et al. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate. 2011;71(3): 326-31. doi: 10. 1002/pros. 21246.
29. Yaman Agaoglu F, Kovancilar M, Dizdar Y, Darendeliler E, Holdenrieder S, Dalay N, et al. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. Tumour Biol: J Int Soc for Oncodevelopmental Biol and Med. 2011;32(3): 583-8. doi: 10. 1007/s13277-011-0154-9.
30. Selth LA, Townley S, Gillis JL, Ochnik AM, Murti K, Macfarlane RJ, et al. Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease. Int J Cancer. 2012;131(3): 652-61. doi: 10. 1002/ijc. 26405.
31. Mahn R, Heukamp LC, Rogenhofer S, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology. 2011;77(5): 1265 e9-16. doi: 10. 1016/j. urology. 2011. 01. 020.
32. Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. The oncologist. 2010;15(7): 673-82. doi: 10. 1634/theoncologist. 2010-0103.
33. Zheng C, Yinghao S, Li J. MiR-221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2. Med Oncol. 2012;29(2): 815-22. doi: 10. 1007/s12032-011-9934-8.
34. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012;72(13): 1469-77. doi: 10. 1002/pros. 22499.
35. Chen ZH, Zhang GL, Li HR, Luo JD, Li ZX, Chen GM, et al. A panel of five circulating microRNAs as potential biomarkers for prostate cancer. Prostate. 2012;72(13): 1443-52. doi: 10. 1002/pros. 22495.
36. Jung K. A review of expression profiling of circulating microRNAs in men with prostate cancer. BJU Int. 2013;111(1): 3-4. doi: 10. 1111/j. 1464-410X. 2012. 11257. x.
37. Olmos D, Brewer D, Clark J, Danila DC, Parker C, Attard G, et al. Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. The lancet Oncol. 2012;13(11): 1114-24. doi: 10. 1016/S1470-2045(12)70372-8.
38. Ross RW, Galsky MD, Scher HI, Magidson J, Wassmann K, Lee GS, et al. A whole-blood RNA transcript-based prognostic model in men with castration-resistant prostate cancer: a prospective study. The lancet Oncol. 2012;13(11): 1105-13. doi: 10. 1016/S1470-2045(12)70263-2.